ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Rapid Non-Invasive Imaging Of Biochemical Composition In Breast Tumor Margins

April 24, 2009

Telatinib Demonstrates Positive Results in First-Line Treatment

June 24, 2011

Cooperative Group Trials Approved By NCI Are Listed

August 26, 2005

Cancer Facts & Figures: Cancer Mortality Down 20 Percent Since 1991

January 25, 2013

Cancer Groups Fear Clinical Trials Coverage Will Not Be Implemented Across Exchanges

July 3, 2013

Cooperative Group Chairman Objects “Personal” Comments, Other Deficiencies In Peer Review

January 16, 1981